EUCTR2020-002931-32-IT进行中（未招募）1 期
A Phase 3 open-label, multicenter, extension study to evaluate the longterm safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration -
APELLIS PHARMACEUTCIALS, INC.0 个研究点目标入组 1,200 人开始时间: 2021年10月18日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Ocular-specific inclusion criteria apply to the study eye only.
- •1. Participated in APL2-103 (NCT03777332) or completed the treatment at Month 24 of either APL2-303 (Derby, NCT03525613) or APL2-304 (Oaks, NCT03525600). Specifically, for the APL2-303 and APL2-304 studies, the
- •following criterion also applies:
- •a. Subjects who did not permanently discontinue treatment but missed the Month 24 visit are also eligible to participate in this extension study; however, to be eligible, these subjects must be screened within 60 daysfrom the last day of the expected Month 24 visit window for the antecedent study.
- •2. Clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the investigator.
- •3. Female subjects must be:
- •a. Women of nonchildbearing potential, or
- •b. Women of childbearing potential (WOCBP) with a negative serum pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study and 90 days after their last dose of pegcetacoplan, and refrain from breastfeeding for the duration of the study.
- •4. Males with female partners of childbearing potential must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and for 90 days after their last dose of pegcetacoplan.
- •5. Willing and able to give informed consent and to comply with the study procedures and assessments.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1160
排除标准
- •Ocular-specific exclusion criteria apply to the study eye only.
- •1. Subjects who permanently discontinued the study drug prior to Month 24 in the APL2-304 or APL2-304 studies and only for safety assessments. Temporary pause of the study drug is not exclusionary.
- •2. Presence of an active ocular disease that, in the opinion of the investigator, compromises or confounds visual function, including, but not limited to, macular hole or other macular diseases (eg, clinically significant epiretinal membrane). Benign conditions in the opinion of the investigator such as peripheral retinal dystrophy are not
- •exclusionary.
- •3. Any contraindication to IVT injection including current ocular or periocular infection.
- •4. Medical or psychiatric condition that, in the opinion of the investigator, is clinically significant and not suitable for study participation or make consistent follow-up over the 36-month treatment period unlikely.
- •5. Known hypersensitivity to fluorescein sodium for injection or hypersensitivity to pegcetacoplan or any of the excipients in pegcetacoplan solution.
- •6. Pregnancy, breastfeeding, or positive pregnancy test.
研究者
相似试验
进行中（未招募）
1 期
Clinical research study involving an intravitreal injection in the eye with Pegcetacoplan for the treatment of Geographic Atrophy Secondary to Age-Related Macular DegeneratioGeographic Atrophy Secondary to Age-Related Macular DegenerationMedDRA version: 20.1Level: LLTClassification code 10063947Term: Geographic atrophySystem Organ Class: 10015919 - Eye disordersEUCTR2020-002931-32-NLApellis Pharmaceuticals Inc.1,200
进行中（未招募）
1 期
Clinical research study involving an intravitreal injection in the eye with Pegcetacoplan for the treatment of Geographic Atrophy Secondary to Age-Related Macular DegeneratioGeographic Atrophy Secondary to Age-Related Macular DegenerationMedDRA version: 20.1Level: LLTClassification code 10063947Term: Geographic atrophySystem Organ Class: 10015919 - Eye disordersEUCTR2020-002931-32-CZApellis Pharmaceuticals Inc.1,200
进行中（未招募）
1 期
Clinical research study involving an intravitreal injection in the eye with Pegcetacoplan for the treatment of Geographic Atrophy Secondary to Age-Related Macular DegeneratioEUCTR2020-002931-32-DEApellis Pharmaceuticals Inc.1,200
进行中（未招募）
1 期
Clinical research study involving an intravitreal injection in the eye with Pegcetacoplan for the treatment of Geographic Atrophy Secondary to Age-Related Macular DegeneratioGeographic Atrophy Secondary to Age-Related Macular DegenerationMedDRA version: 20.1Level: LLTClassification code 10063947Term: Geographic atrophySystem Organ Class: 100000004853EUCTR2020-002931-32-ESApellis Pharmaceuticals Inc.1,200
进行中（未招募）
1 期
Clinical research study involving an intravitreal injection in the eye with Pegcetacoplan for the treatment of Geographic Atrophy Secondary to Age-Related Macular DegeneratioGeographic Atrophy Secondary to Age-Related Macular DegenerationMedDRA version: 20.1Level: LLTClassification code 10063947Term: Geographic atrophySystem Organ Class: 100000004853EUCTR2020-002931-32-PLApellis Pharmaceuticals Inc.1,200